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Why was the cohort set up?
Influenza is a common, highly contagious respiratory virus
which infects all age groups, causing a range of outcomes
from asymptomatic infection and mild respiratory disease
to severe respiratory disease and death.1 If infected, the
adaptive immune system produces a humoral (antibody)
and cell-mediated (T cell) immune response to fight the in-
fection.2 Influenza viruses continually evolve through anti-
genic drift, resulting in slightly different ‘seasonal’
influenza strains circulating each year. Population-level
antibody immunity to these seasonal viruses builds up over
time, so in any given season only a proportion of the popu-
lation is susceptible to the circulating strains. Occasionally,
influenza A viruses evolve rapidly through antigenic shift
by swapping genes with influenza viruses usually circulat-
ing in animals. This process creates an immunologically
distinct virus to which the population may have little to no
antibody immunity. The virus can result in a pandemic if a
large portion of the population is susceptible and the virus
is easily spread.1
International influenza surveillance is typically based
upon cases seeking medical care.3–5 However, this focus
greatly underestimates the true community burden of sea-
sonal influenza: the majority of cases are mild and self-lim-
iting, with asymptomatic infections accounting for 25% to
75% of all infections.6,7 Effective influenza control re-
quires knowledge of disease burden and factors affecting
influenza transmission. Existing parameters for mathemat-
ical models of influenza interventions are largely derived
from household cohort studies conducted in the USA be-
tween 1948 and 1981.8–10 Since then there have been pro-
found social changes affecting population contact and
mixing patterns that are likely to impact on influenza
transmission. These changes include more women
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working, more children attending day care, more commut-
ing and international travel and increased vaccine cover-
age. Evolutionary changes to circulating viruses may affect
transmission dynamics, patterns of clinical illness and the
adaptive immune responses elicited.1,11 Rapid advances in
laboratory methods have also occurred, providing unique
opportunities to investigate immune correlates, both hu-
moral and T cell based, with influenza infection rates and
disease severity.11,12
The initial Flu Watch cohort, funded by the UK
Medical Research Council (MRC), began in 2006 as a col-
laboration between epidemiologists at the Centre for
Infectious Disease Epidemiology at University College
London (UCL), virologists and mathematical modellers
from the Health Protection Agency (HPA, now Public
Health England), immunologists at the MRC Human
Immunology Unit at Oxford University and the MRC
General Practice Research Framework (GPRF). It aimed to
estimate community burden of influenza and influenza-like
illness, generate up-to-date knowledge of demographic, so-
cial and behavioural factors affecting influenza transmis-
sion, measure antibody and T cell immune responses to
influenza and to use knowledge generated to inform mod-
elling parameters. In addition, a pandemic preparedness
cohort was envisioned, in which participants already famil-
iar with the study consented to be re-contacted in the event
of a pandemic, to allow rapid redeployment of the study.
When the 2009 influenza AH1N1 pandemic arose, fur-
ther funding was secured jointly from the MRC and
Wellcome Trust, allowing continued follow-up and an ex-
pansion in cohort size. New collaborators for this phase
included the MRC Centre for Outbreak Analysis and
Modelling, the Wellcome Sanger Institute, the Primary
Care Research Network and additional epidemiology and
public health experts from the HPA. Additional study aims
were to inform the national and international response to
the current and future pandemics. Specific objectives were
to examine clinical profiles of illness, estimate population
infection denominators and case fatality risk, describe epi-
demiological characteristics of the infection in real-time,
monitor changes in population behaviour, and investigate
access to services, attitudes to and uptake of antivirals and
vaccine, and immunity to infection in order to inform vac-
cination policy and development. During the pandemic, Flu
Watch also provided control data and samples for studies
of severe influenza (MOSAIC) and studies of influenza in-
fection risk in people working with pigs (COSI).13,14
Who is in the cohort?
Households were recruited from registers of 146 volunteer
general practices (GP) across England, who formed part of
the MRC GPRF or (from the 2009 pandemic onwards) the
Primary Care Research Network. Participants were se-
lected from GP lists by computer-based random number
generation. GPs sent invitation letters inviting the ran-
domly selected person and their household to participate.
Although it was recognized that this would bias invitations
towards larger households, such as those with children,
this was accepted as the role of children in influenza trans-
mission was an important research question. Weighting by
the inverse of household size in analyses was planned to ac-
count for this sampling design.
To be eligible to participate, the whole household had
to agree to take part in follow-up over the coming winter,
with adults aged  16 years agreeing to have blood sam-
ples taken. Exclusion criteria included household size > 6
people, individuals with terminal illness, severe mental ill-
ness or incapacity and heavy involvement in other ongoing
research. GPs reviewed invitation lists and removed any-
one meeting these criteria, before sending letters. Cohorts
were recruited to allow follow-up of participants over six
influenza seasons—the 2006/07, 2007/08 and 2008/09
periods of seasonal influenza circulation, the summer and
winter waves of the 2009 pandemic and the first post-pan-
demic season 2010/11. From season 3 (2008/09) onwards,
previous participants were invited to take part again.
In season 1, invitation letters were sent to 2300 house-
holds from 42 practices, and 602 individuals from 243
households agreed to participate. In subsequent seasons
the response rate was not monitored as practices (rather
than the university study team) sent the invitation letters
and not all returned data on numbers sent. Compared with
the English population, young adults, non-White ethnic
groups, people living in socially deprived areas and those
living in the North of England, West Midlands and
London were under-represented in the Flu Watch cohort
(Table 1).
How often have they been followed up?
The basic cohort design
Baseline/pre-season phase
A baseline visit was made to the household at enrolment,
during which a research nurse collected blood samples
for serological and T cell analysis from all adults aged
16 years or older. Blood sampling was optional for those
aged 5–15 years and not done in those under 5 years of
age. Visits occurred in the evenings, as bloods had to be
couriered overnight to Oxford for early morning ana-
lysis of T cells. The serum samples collected we recentri-
fuged, frozen and later batch-tested for influenza
antibodies by the HPA. Nurses assisted families with a
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series of laptop-based surveys collecting information on
basic demographics, health and chronic illness, respira-
tory hygiene, household structure and relationships, ac-
commodation, contacts and activities. Households
received participant packs containing paper illness dia-
ries, thermometers and nasal swab kits including instruc-
tions on their use and the viral transport medium to be
stored in the refrigerator.
Active follow-up during influenza season
In order to obtain reliable measures of the number of ill-
nesses, we actively contacted participants every week with
automated telephone calls to assess the presence or absence
of respiratory illness in each household member. For
each respiratory illness, participants were reminded to fill
in a prospective paper illness diary. These collected
information on illness onset date, temperature and pres-
ence and severity of symptoms such as feeling feverish,
headache, muscle aches, cough and sore throat. Diaries
also collected data on contact patterns and activities before
and during illness. Participants took a nasal swab on day 2
of any respiratory illness for polymerase chain reaction
(PCR) analysis of influenza, respiratory syncytial virus
(RSV), human metapneumovirus (hMPV), rhinovirus, cor-
onavirus, adenovirus and parainfluenzavirus. During the
first season, swabbing was limited to periods of influenza
circulation. The Sanger Institute genetically sequenced
some of the viral isolates from the summer and winter
waves of the pandemic (seasons 4–5).
In addition, all participants completed one-off activ-
ity and contact paper diaries on at least 1 pre-determined
weekday and 1 weekend day during the active follow-up
Table 1. Baseline characteristics of responders by season compared with national averages
National Nov 2006 to
Mar 2007
Season 1
Nov 2007 to
Mar 2008
Season 2
Nov 2008 to
Mar 2009
Season 3
May 2009 to
Sep 2009
Season 4
Oct 2009 to
Feb 2010
Season 5
Nov 2010 to
Mar 2011
Season 6
GP practices/
households/
persons (n)
42/243/602 43/310/779 37/309/729 41/332/797 127/1460/3552 51/361/901
Age group
0 to 4 years 6% 38 (6.31%) 42 (5.39%) 37 (5.08%) 36 (4.52%) 179 (5.04%) 45 (4.99%)
5 to 15 11% 87 (14.45%) 110 (14.12%) 99 (13.58%) 109 (13.68%) 501 (14.10%) 131 (14.54%)
16 to 44 42% 151 (25.08%) 258 (33.12%) 172 (23.59%) 192 (24.09%) 848 (23.87%) 206 (22.86%)
45 to 64 25% 203 (33.72%) 272 (34.92%) 267 (36.63%) 293 (36.76%) 1225 (34.49%) 344 (38.18%)
65þ 16% 123 (20.43%) 97 (12.45%) 154 (21.12%) 167 (20.95%) 799 (22.49%) 175 (19.42%)
Gender
Male 49% 281 (46.68%) 366 (46.98%) 340 (46.64%) 377 (47.30%) 1740 (48.99%) 455 (50.50%)
Female 51% 321 (53.32%) 413 (53.02%) 389 (53.36%) 420 (52.70%) 1812 (51.01%) 446 (49.50%)
Region
North 28% 99 (16.45%) 89 (11.42%) 100 (13.72%) 106 (13.30%) 320 (9.01%) 115 (12.76%)
West Midlands 11% 42 (6.98%) 96 (12.32%) 46 (6.31%) 53 (6.65%) 179 (5.04%) 53 (5.88%)
East & East Midlands 20% 122 (20.27%) 120 (15.40%) 124 (17.01%) 118 (14.81%) 1456 (40.99%) 321 (35.63%)
London 15% 28 (4.65%) 77 (9.88%) 26 (3.57%) 28 (3.51%) 270 (7.60%) 65 (7.21%)
South East 16% 100 (16.61%) 117 (15.02%) 107 (14.68%) 155 (19.45%) 319 (8.98%) 110 (12.21%)
South West 10% 211 (35.05%) 280 (35.94%) 326 (44.72%) 337 (42.28%) 1008 (28.38%) 237 (26.30%)
Vaccine
Vaccinateda 115 (19.10%) 130 (16.69%) 169 (23.18%) 0 (0%) 157 (4.42%) 186 (20.64%)
Unvaccinated 462 (76.74%) 632 (81.13%) 527 (72.29%) 797 (100%) 3159 (88.94%) 715 (79.36%)
Unknown 25 (4.15%) 17 (2.18%) 33 (4.53%) 0 (0%) 236 (6.64%) 0 (0%)
Index of Multiple
Deprivation quintile
1 (most deprived) 20% 37 (6.15%) 39 (5.01%) 28 (3.84%) 18 (2.26%) 98 (2.76%) 29 (3.22%)
2 20% 88 (14.62%) 126 (16.17%) 91 (12.48%) 62 (7.78%) 310 (8.73%) 82 (9.10%)
3 20% 164 (27.24%) 235 (30.17%) 238 (32.65%) 146 (18.32%) 915 (25.76%) 221 (24.53%)
4 20% 162 (26.91%) 250 (32.09%) 187 (25.65%) 146 (18.32%) 938 (26.41%) 280 (31.08%)
5 (least deprived) 20% 151 (25.08%) 129 (16.56%) 185 (25.38%) 425 (53.32%) 1291 (56.35%) 289 (32.08%)
Ethnicity White 75% 557 (97.89%) 733 (95.44%) 666 (99.11%) 730 (99.05%) 3306 (97.70%) 846 (97.80%)
Non-White 25% 5 (2.11%) 3 (4.56%) 6 (0.89%) 7 (0.95%) 78 (2.30%) 19 (2.20%)
*Vaccinated for that influenza season (before or during follow-up).
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period. These diaries collected information on where
participants were (i.e. at home, at work etc.), whether
they had contact with crowds and the number, dur-
ation and age groups of personal contacts throughout
the day.
Post-season phase
At the end of follow-up, nurses made a final household
visit to take a follow-up blood sample (for paired serology)
and assist participants with an exit survey. Nurses also
checked participants’ medical records for information on
chronic illnesses, influenza and pneumococcal vaccin-
ations, prescriptions, GP consultations, hospitalizations
and deaths.
Evolution of data collection
The cohort evolved over time to maximize system reliabil-
ity, minimize the number of data sources and allow
increased recruitment during the pandemic. In season 3 we
offered participants the option of moving from paper ill-
ness diaries with weekly automated phone calls to weekly
emailed surveys with or without optional SMS reminders.
For the pandemic and post-pandemic cohort, most surveys
moved to a custom-built website for self-completion. In
order to achieve real-time monitoring of illnesses during
the pandemic, participants were emailed a link to a retro-
spective online weekly survey and provided with laminated
wipe-clean charts at home to record daily symptoms as a
memory aid.
In season 3 there were additional one-off surveys col-
lecting data on indoor and outdoor temperature and hu-
midity, travel patterns and non-response to weekly
surveys. During seasons 5 and 6 we added questions to
existing surveys on attitudes towards influenza vaccination
and antivirals. In season 6 we included quality of life
questions.15
Evolution of cohort design
The cohort design evolved with the emergence of the
novel H1N1 pandemic strain during season 3.We con-
tinued active follow-up through the UK summer wave of
the pandemic (season 4). For the UK winter wave of the
pandemic (season 5), the study split into three separate
cohorts: T cell (comprising both previous and newly re-
cruited participants), Serology and Virology (both com-
prising new participants). For the T cell cohort,
continuing participants used the spring blood sample
from season 3 as a baseline sample. They also gave a
pre-vaccination blood sample to allow distinction of
antibody rises caused by infection rather than
vaccination. This was particularly important for the
winter wave of the pandemic, as we anticipated wide-
spread vaccination. The Serology cohort was identical
but lacked T cell samples. For the Virology cohort, no
blood samples were taken. This allowed for rapid re-
cruitment of a large number of participants (n¼ 1778)
to increase the accuracy of weekly estimates of illness
rates during the pandemic, with minimal nurse time
required. All nasal swabs were tested for influenza A
and B, RSV and hMPV but, due to the large number of
samples generated during the pandemic, only a selection
in seasons 5 and 6 were tested for other viruses.
Loss to follow-up and missing data
Retention of enrolled participants throughout the cohorts
was good. Figure 1 displays the number of enrolled partici-
pants each week, with arrows pointing out the staggered
starts and exits of the cohorts along with other important
dates. Loss to follow-up came in two main varieties: non-
response to weekly contact and loss to follow-up for paired
blood samples.
We obtained weekly responses from 87.3% of follow-
up weeks overall, which increased to 88.4% if we exclude
periods when there were technical difficulties with our
automated phone calls (1 week in season 1 and 4 weeks in
season 2). Response completeness generally increased after
the introduction of email and online surveys in season 3
(Table 2). Only 12.4% of households were classified as
poor responders (responding to < 70% of follow-up
weeks). Poor response appeared to be more common as de-
privation increased.
We obtained paired blood samples from 80% of partici-
pants required to provide them and from 27% of partici-
pants aged 15 and under, for whom blood samples were
optional (Table 3).
What has been measured?
The three main clinical outcomes were: (i) influenza-like-
illness (ILI), defined as a respiratory illness with cough
and/or sore throat and fever > 37.8C;(ii) PCR-confirmed
influenza illness; and (iii) influenza seroconversion, defined
as a 4-fold titre rise in strain-specific antibody titres in un-
vaccinated individuals. Table 4 summarizes the data
and biological samples collected during baseline, active fol-
low-up and post-season phases. We additionally linked
participants’ data to small area statistics such as the index
of multiple deprivation and rural/urban indicators.16,17
Details of the T cell methodology have been described
previously.18–20
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What has been found? Key findings and
publications
Our first publication provided comprehensive national es-
timates of clinical and sub-clinical disease burden in the
community regardless of consultations, and allowed com-
parison between seasonal and pandemic influenza.2 We
found that on average, influenza infected 18% of unvac-
cinated people each winter and up to 75% of these infec-
tions were asymptomatic. Approximately 25% of
infections were PCR confirmed and only 17% of people
with PCR-confirmed disease sought medical attention;
Figure 2 indicates how the primary care-based surveillance
underestimated the burden of infection in the community.
Results were similar between pandemic and seasonal influ-
enza, although people infected with the 2009 pandemic
strain had less severe symptoms than those infected with
seasonal H3N2 strains.
Our second publication provided strong evidence that
naturally occurring, cross-protective T cell immunity pro-
tects those infected with influenza against developing
disease in seasonal and pandemic periods.16 This protec-
tion was independent of baseline antibodies and protective
levels of influenza-specific T cells were found in 43% of
the population. These findings help explain why such a
large proportion of infections remain asymptomatic and
have implications for the development of cross-protective
‘universal’ vaccines based on this response.
In order to evaluate different methods of collecting data
during a pandemic, we compared prospectively collected Flu
Watch data on illnesses and vaccine uptake with retrospect-
ively collected data from the Health Survey for England.21
We found that retrospectively collected data underestimated
disease burden but accurately estimated vaccine uptake
when compared with prospectively collected data.
Current work includes an analysis of occupational ex-
posure to pigs as a risk factor for human infection with
swine and human influenza viruses; age as a predictor of T
cell responses; and a comparison of serological pandemic
infection rates from Flu Watch and the Health Survey for
England.
Figure 1. Number of enrolled participants, baseline/pre-season bleed periods and different cohorts and data collection methods over time. ‘Survey
Methods’ boxes used to indicate which methods were used to follow up participants in each season
*T cell cohorts included T cell, serological and virological (PCR) measurements.
** Serology cohorts included serological and virological (PCR) measurements.
*** Virology cohort only included virological (PCR) measurements.
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Table 2. Characteristics of non-responding households (i.e. households with  30% missing weeks)
Household characteristics Good responders Poor responders Total
(< 30% missing weeks) ( 30% missing weeks)
N % N % N
Overall 2640 87.6 372 12.4 3012
Season
Nov 2006 to Mar 2007 (1) 199 81.9 44 18.1 243
Nov 2007 to Mar 2008 (2) 202 65.8 105 34.2 307
Nov 2008 to Mar 2009 (3) 287 92.9 22 7.1 309
May 2009 to Sep 2010 (4) 246 74.1 86 25.9* 332
Oct 2009 to Feb 2010 (5) 1370 93.8 90 6.2 1460
Nov 2010 to Mar 2011 (6) 336 93.1 25 6.9 361
Social class
Managerial and professional 712 87.6 101 12.4 813
Intermediate occupations 362 87.9 50 12.1 412
Small employers and own-account workers 209 85.3 36 14.7 245
Lower supervisory and technical occupations 111 84.1 21 15.9 132
Semi-routine and routine occupations 441 86.5 69 13.5 510
Retired 497 94 32 6 529
Student 109 84.5 20 15.5 129
missing 199 82.2 43 17.8 242
Index of Multiple Deprivation quintile
1 (most deprived) 85 81 20 19 105
2 255 84.7 46 15.3 301
3 704 86.9 106 13.1 810
4 732 89.6 85 10.4 817
5 (least deprived) 864 88.3 115 11.7 979
Rural/urban
Urban>10k 1505 86.7 230 13.3 1735
Town and fringe 373 90.3 40 9.7 413
Village, hamlet and isolated dwellings 643 89.9 72 10.1 715
Missing 119 79.9 30 20.1 149
Household size
1 354 84.5 65 15.5 419
2 1405 89.7 162 10.3 1567
3 344 85.1 60 14.9 404
4 407 87.3 59 12.7 466
5 109 84.5 20 15.5 129
6 21 77.8 6 22.2 27
Number of children in the household
0 1932 89.1 236 10.9 2168
1 247 81.8 55 18.2 302
2 360 85.1 63 14.9 423
3 83 86.5 13 13.5 96
4 18 78.3 5 21.7 23
Region
North 305 87.9 42 12.1 347
West Midlands 164 84.1 31 15.9 195
East and East Midlands 828 90.5 87 9.5 915
London 164 84.5 30 15.5 194
South East 314 83.5 62 16.5 376
South West 865 87.8 120 12.2 985
aWe believe the poor response in this season may be due to summer holidays.
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What are the main strengths and
weaknesses?
Flu watch is a large community cohort study broadly repre-
sentative of the population of England. It is the first modern-
day household study of influenza transmission in a temperate
climate, comparable to the landmark Tecumseh studies of the
1960s and 70s.22 A major strength is the inclusion of different
household types (rather than just households with children,
as in earlier studies) which allows influenza infections to be
explored across the whole of society. We used highly active
methods of surveillance for influenza and other respiratory
Table 3. Characteristics of Participants with and without missing blood samples by whether or not those blood samples were
required or optional
Individual characteristics Participants with Mandatory Bloods Participants with Optional Bloods
Paired Bloods Missing Blood Total Paired Bloods Missing Blood Total
N % N % N N % N % N
Overall 3114 80.5 754 19.5 3868 181 27.0 489 73.0 670
Season
Nov 2006 to Mar 2007 (1) 422 88.5 55 11.5 477 31 35.6 56 64.4 87
Nov 2007 to Mar 2008 (2) 503 80.2 124 19.8 627 27 24.5 83 75.5 110
Nov 2008 to Mar 2009 (3) 489 82.5 104 17.5 593 23 23.2 76 76.8 99
Oct 2009 to Feb 2010 (5) 1120 77.5 326 22.5 1446 70 28.8 173 71.2 243
Nov 2010 to Mar 2011 (6) 580 80.0 145 20.0 725 30 22.9 101 77.1 131
Gender
Male 1441 79.8 363 20.1 1804 95 27.7 248 72.3 343
Female 1673 81.0 391 18.9 2064 86 26.3 241 73.7 327
Age group
Age 5 to 15 years n/a n/a 181 27.0 489 73.0 670
Age 16 to 44 years 874 74.0 307 26.0 1181 n/a n/a
Age 45 to 64 years 1446 82.4 309 17.6 1755 n/a n/a
Age 65 and over 794 85.2 138 14.8 932 n/a n/a
Region
North 365 73.9 129 26.1 494 25 28.1 64 71.9 89
West Midlands 231 84.3 43 15.7 274 10 23.8 32 76.2 42
East & East Midlands 817 79.7 208 20.3 1025 43 23.0 144 77.0 187
London 158 84.5 29 15.5 187 13 30.2 30 69.8 43
South East 444 79.7 113 20.3 557 25 33.3 50 66.7 75
South West 1099 82.6 232 17.4 1331 65 27.8 169 72.2 234
Vaccine
Vaccinateda 953 84.0 181 16.0 1134 14 29.8 33 70.2 47
Unvaccinated 2072 81.1 484 18.9 2554 165 27.9 427 72.1 592
Unknown 89 49.4 91 50.6 180 2 6.5 29 93.5 31
Index of Multiple Deprivation (National quintile)
1 (most deprived) 110 86.6 17 13.4 127 6 20.7 23 79.3 29
2 363 84.6 66 15.4 429 21 28.4 53 71.6 74
3 893 81.8 199 18.2 1092 59 30.1 137 69.9 196
4 922 83.3 185 16.7 1107 50 27.5 132 72.5 182
5 (least deprived) 826 74.2 287 25.8 1113 45 23.8 144 76.2 189
Ethnicity
White 2654 82.8 551 17.2 3205 161 29.1 392 70.9 553
Non-White 49 70.0 21 30.0 70 1 9.1 10 90.9 11
Missing 411 69.3 182 30.7 593 19 17.9 87 82.1 106
Rural/Urban
Urban 1895 82.5 403 17.5 2298 116 26.3 325 73.7 441
Town and Fringe 426 82.4 91 17.6 517 23 33.3 46 66.7 69
Village, hamlet and isolated Dwellings 793 82.1 173 17.9 966 42 30.9 94 69.1 136
Missing 0 0.0 87 100.0 87 0 0.0 24 100.0 24
*Vaccinated for that influenza season (before or during follow-up).
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Table 4. Questionnaire data and biological samples collected in three data collection periods
Phase Data type Measurement Season
1 2 3 4 5 6
Baseline/Pre-season Self-reported surveys Basic demographic, socioeconomic,
health, vaccination and potential
risk factors for influenza
X X X X X X
Quality of life (EQ5D) X
Blood samples H1N1, H3N2 and Flu B serologya X X X
H1N1pdm09 serologicala X X X
T cell analysisb X X X X
Active follow-up Self-reported surveys Timing and characteristics of respira-
tory illnesses (if ill)
X X X X X X
Risk factors in previous week (if ill) X X X
Time off work/education (if ill) X X X X
Health-seeking behaviour and medi-
cines taken (if ill)
X X
Full contact and activity diaries (if ill) X X
Basic contact and activities (if ill) X
Influenza vaccination that week X X X
Full contact and activity diaries (one-
off survey)
X X X X X X
Indoor/outdoor temperature and hu-
midity (one-off surveys)
X X X
Detailed travel survey (one-off survey) X
Self-administered nasal swabs RT-PCR Influenza A (H1 and H3 sub-
types), influenza B, RSV and human
metapneumovirus
X X X X X X
RT-PCR influenza A H1N1pdm09 X X X
RT-PCR rhinovirus, coronavirus,
adenovirus and para-influenza
virusc
X X X X X X
Selected viral samples genetically
sequenced
X X X X X X
Blood samplesd H1N1pdm09 serology X
Post-season Self-reported surveys Changed household composition,
pregnancy, vaccination, hospitaliza-
tion, death and air travel
X X X X X X
Illness-reporting behaviour during fol-
low-up
X X X
Attitudes towards vaccination and
antivirals
X X
Medical recordse Chronic illness, vaccination, prescrip-
tions, GP and hospital consultations
and death
X X X X X X
Blood samples H1N1, H3N2 and flu B serologya X X X
H1N1pdm09 serologya X X
T cell analysisb X X
Saliva Samplesf Genetic analysis X X X X X X
aHaemagglutination-inhibition assay.
bPeripheral blood mononuclear cells (PBMC) separated, part of the sample was immediately tested against pools of peptides representing each of the virus pro-
teins in an ex vivo IFN-celispot assay.18,19 The rest of the sample was frozen down for more detailed peptide mapping studies using IFN-celispots and/or in vitro
culture and testing by intracellular cytokine staining to determine CD8/4 restriction. Post-season T cell analysis was only conducted in seasons 1 and 3.
cOnly a selection of nasal swab samples were tested for these viruses in seasons 5 and 6.
dOnly taken from participants in T cell and serology cohorts before influenza vaccination.
eMedical record checks were requested for all participants except those in the virology cohort.
fSaliva was collected in 2011–12 from selected participants participating from all seasons and cohorts.
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viruses, exploiting a range of IT-based technologies including
automated telephone surveys, e-mail, internet and text mes-
sages. Broadly similar methods of follow-up were used across
six influenza seasons, allowing accurate comparisons of dis-
ease burden estimates between seasonal and pandemic influ-
enza despite external factors (such as media reporting during
the pandemic) that may have affected consultation behaviour.
Robust definitions of influenza were based on a range of diag-
nostic methods including real-time symptom reporting, PCR
and serology, allowing the emergence of the 2009 H1N1 pan-
demic strain to be tracked. Serological and virological data
from previous pandemics are either unavailable (1918 H1N1
pandemic), from small samples sizes (1957 H2N2 pan-
demic)23 or from populations with high vaccination rates
which greatly limits interpretation (1968 H3N2 pandemic).22
Historical data on laboratory-confirmed rates of seasonal in-
fluenza mainly come from historical community studies of
families in the USA between 1948 and 1981.10,22,24,25 Flu
Watch is a good example of collaboration between disciplines
(epidemiology, immunology, virology and primary care) and
partners. The study provides a rich source of data on social,
behavioural and biological factors affecting influenza trans-
mission, enabling exploration of many research questions.
Limitations include delays in obtaining funding, ethics
and R&D approval across multiple sites, resulting in delayed
recruitment during the pandemic and fewer participants
overall. Although the initial response to invitation letters was
low, it is unclear if this would bias results. Ideally, cohorts
would have had pre- and post-influenza season bleeds, but
recruitment periods were not perfectly streamlined with in-
fluenza seasons so adjustments for bleed timings were made
during analysis. The study design and data collection meth-
ods evolved in response to experience and changing ques-
tions. Whereas this optimized and streamlined methods, it
also increased complexity of data management.
Can I get hold of the data? Where can I find
out more
For further information about Flu Watch see [http://www.
fluwatch.co.uk/]. Currently data are not open access but
strategic collaborations are welcomed. Please address
enquiries to Professor Andrew Hayward
[a.hayward@ucl.ac.uk].
Flu watch profile in a Nutshell
• Flu Watch is a national prospective cohort study of
influenza in English households.
• It aimed to measure clinical and sub-clinical infection
in the community, investigate socio-demographic
and behavioural risk factors for influenza and
Figure 2. Number of expected events in a surveillance practice serving a population of 10 000: data for a typical influenza season.
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generate novel data on antibody and T cell immun-
ity, to inform influenza control initiatives.
• A total of 5484 participants were recruited from 2205
households randomly selected from registers of par-
ticipating general practices.
• Participants were followed up for 118 158 person-
weeks through six periods of influenza circulation:
the winter seasons 2006/07, 2007/08 and2008/09, the
summer 2009 pandemic wave, the winter 2009/10
pandemic wave and the post pandemic season 2010/
11.
• The dataset comprises a wide range of demo-
graphic, social and behavioural measures, active
weekly surveillance for respiratory illnesses and bio-
logical samples (nasal swabs, serology and T cells).
• Data are not currently open access but strategic col-
laborations are welcomed: enquiries to
[a.hayward@ucl.ac.uk].
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